Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
Clover Health Investments reported quarterly sales of $510.3 million which beat the analyst consensus estimate of $480.25 million by 6.26% and represents a 43.22% decrease over sales of $898.79 million the same period last year.
Clover Health Investments shares climbed 11.2% to $0.8537 on Wednesday.
Here are some other stocks moving in today's mid-day session.
Gainers
- Gaxos.ai Inc. (NASDAQ: GXAI) shares jumped 128.9% to $12.18 after the company announced it acquired the rights to use certain AI-enabled technology from Ultiself.
- Veritone, Inc. (NASDAQ: VERI) gained 52.4% to $2.6076 following strong sales results.
- NuCana plc (NASDAQ: NCNA) gained 50.2% to $0.5869 after the company was granted a US Patent for "Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance."
- The Beauty Health Company (NASDAQ: SKIN) rose 31.9% to $4.7350 after the company reported better-than-expected fourth-quarter revenue results.
- Arq, Inc. (NASDAQ: ARQ) gained 28.3% to $4.4522 after the company reported upbeat fourth-quarter results.
- MicroCloud Hologram Inc. (NASDAQ: HOLO) jumped 26.6% to $6.19.
- Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares gained 26.2% to $0.1055.
- Nature's Sunshine Products, Inc. (NASDAQ: NATR) jumped 24.7% to $21.47 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 net sales guidance.
- Heron Therapeutics, Inc. (NASDAQ: HRTX) gained 24.7% to $2.9428 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5.
- Li-Cycle Holdings Corp. (NASDAQ: LICY) shares gained 23.2% to $0.7233. Li-Cycle shares jumped 46% on Tuesday after the ...